By Samuel Okafor, BSN, RN, Registered Nurse, Endocrinology. Medically reviewed by Dr. Anika Rao, MD, Board-Certified Internal Medicine.
When Rachel, a 46-year-old project manager in Austin, stepped on the scale at her 36-week follow-up, she was down 42 pounds from where she'd started on tirzepatide 10 mg. "I kept waiting for the number to bounce back up, because that's what always happened before," she told her prescriber. "This time it just kept going." Her result was above the trial average. She knew that. She also knew a colleague on the same dose had lost 18 pounds in the same window. Same drug, same schedule, wildly different outcomes. That range is the reality tirzepatide before and after stories almost never capture.
This article tries to capture it: the trials, the mechanism, the dosing variables, the comparisons, and the practical takeaways when the headline numbers meet actual human biology.
This article is part of the FormBlends ultimate guide to compounded tirzepatide and the GLP-1 Long-Term & Maintenance hub.
What you need to know up front
- Semaglutide is a GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist. That distinction matters more than most social-media posts suggest.
- In the only head-to-head trial (SURPASS-2), tirzepatide beat semaglutide 1 mg on both weight loss and A1c reduction in adults with type 2 diabetes.
- Indirect comparisons for obesity indications also tend to favor tirzepatide, but individual variance is significant.
- Compounded tirzepatide is not FDA-approved. The FDA does not pre-review compounded medications.
The drugs and how they differ
Liraglutide (Saxenda) is a daily injection, FDA-approved for weight management since 2014, with the longest post-marketing safety record of the bunch. Semaglutide and tirzepatide are both weekly injections, which makes adherence meaningfully easier for most patients.
Here's the thing about mechanism: all three drugs activate the GLP-1 receptor. That receptor sits on pancreatic islet cells, on brain structures that regulate appetite, and on cells lining the GI tract. Activation triggers glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and reduces the central experience of hunger and food reward.
Tirzepatide adds a second target. It also activates the GIP receptor. That's the headline mechanistic difference from pure GLP-1 agonists. Pre-clinical work suggests GIP agonism may improve GI tolerability at higher doses and affect adipose tissue physiology directly, but the exact clinical contribution of GIP activity is still being sorted out. It's promising, not settled.
Semaglutide and liraglutide differ from each other mostly in pharmacokinetics. Semaglutide has a much longer half-life, which is why it only needs a weekly injection. Liraglutide requires one every day.
What the trials actually showed
The numbers people cite most come from two landmark trials.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →STEP 1 reported a mean weight reduction of approximately 14.9 percent at 68 weeks with semaglutide 2.4 mg, versus 2.4 percent with placebo.
SURMOUNT-1 reported tirzepatide weight reductions of roughly 15 percent, 19.5 percent, and 20.9 percent at the 5, 10, and 15 mg doses over 72 weeks.
Read those side by side and tirzepatide looks like the clear winner. And it probably is, on average. But "on average" is doing a lot of heavy lifting in that sentence. SURMOUNT-1 reported substantial response differences within the same dose arm. Some participants at 5 mg outperformed others at 15 mg. Biology is messy.
A few more trials worth knowing:
SURPASS-2 is the only direct head-to-head: tirzepatide versus semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Tirzepatide won on both weight and A1c endpoints. One caveat: the semaglutide comparator was 1 mg (the diabetes dose), not the 2.4 mg obesity dose.
SELECT (Lincoff et al., NEJM 2023) studied cardiovascular outcomes of semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity. It showed cardiovascular benefit. Tirzepatide's cardiovascular outcome data are not yet as mature. That gap matters.
SURMOUNT-2 (Garvey et al., Lancet 2023) evaluated tirzepatide in adults with obesity and type 2 diabetes over 72 weeks.
SURMOUNT-3 (Wadden et al., Nat Med 2023) tested tirzepatide after a 12-week intensive lifestyle intervention lead-in, essentially asking whether the drug could extend the gains from diet and exercise.
Trial averages are exactly that. Averages. They describe what a representative participant experienced under controlled conditions, not what any individual outside the trial will necessarily experience.
When the trial world meets the real world
Real-world data consistently show smaller average effects than randomized trials. The reasons are predictable: trials enforce adherence, provide protocol-driven lifestyle interventions, and exclude patients with complicating comorbidities. The gap is real but not large enough to reverse the qualitative conclusion of the trial data.
The boring truth? Adherence is the single largest variable in real-world outcome variance. Patients who reach the maintenance dose and stay on therapy for 12 or more months consistently outperform those who discontinue early. Not because they're special. Because the drug needs time to work at full dose.
Across the entire GLP-1 class, the strongest predictor of long-horizon outcome is simply months on therapy at or near the maintenance dose. Everything else (diet composition, exercise type, supplement stack) matters less than that. Not zero. Less.
The variables that actually move individual results
If adherence is the biggest lever, here's what fills out the rest of the list: baseline BMI, baseline glycemic status, age, sex, body composition, dietary patterns, sleep quality, resistance-training exposure, comorbidities, concurrent medications, and the patient's own goals and constraints.
No single variable dominates across all patients. The variance in real-world results is the joint effect of many small inputs. Which is also what makes a documented log so valuable. Write down your weight, your meals, your side effects, your energy. Not obsessively, but consistently. The log makes the variables visible, and it gives your prescriber something to work with beyond "I think things are going okay."
Practical advice that actually helps
For the patient: Pick an injection day and protect it. Build the tolerability plan (meal size, food choices, anti-nausea strategy) before week one, not after you spend a weekend on the couch. Plan for plateaus rather than fearing them. Plateaus are normal, not a sign the drug stopped working. Treat the prescriber visit as the venue for course correction, not a formality.
For the prescriber: Titrate to tolerability. Ask explicitly about lifestyle inputs at every visit. Revisit the long-horizon plan periodically, because a patient's goals at month three may be very different from their goals at month nine.
Where this falls apart most often is the switch scenario. Yes, switching from semaglutide to tirzepatide (or the reverse) is a routine clinical decision. But the new agent should be started at its lowest dose and re-titrated. Jumping to a "dose-equivalent" on day one is a recipe for avoidable GI misery.
What to watch going forward
Several open questions are worth tracking. Long-horizon comparative effectiveness data between tirzepatide and semaglutide at their respective obesity doses would be enormously clarifying. Cardiovascular outcome data for tirzepatide specifically are still maturing. Additional incretin-targeted agents are in the pipeline. The regulatory and reimbursement landscape continues to shift.
My genuinely opinionated take: the signal worth tracking in this category is peer-reviewed publication, not industry press releases and not TikTok transformation videos. The peer-reviewed evidence base is what holds up across the next decade. Press releases are marketing wearing a lab coat.
Related reading
- Saxenda For Weight Loss: Complete Guide
- 2.5 Mg/Ml: Complete Guide
- Does prozenith work for weight loss?
Frequently asked questions
Is this something I should discuss with a clinician?
Yes. Any question that affects how a prescription medication is dosed, stored, or administered is worth raising with your prescriber. This article is general education, not a substitute for individualized clinical guidance.
Which option produces more weight loss on average?
In SURPASS-2, tirzepatide produced greater weight reduction than semaglutide 1 mg in adults with type 2 diabetes over 40 weeks. Indirect comparisons for obesity indications also tend to favor tirzepatide, but individual response varies meaningfully, and the head-to-head dataset at obesity-indication doses is limited.
Is one option safer than the other?
Both share the GLP-1 side-effect profile and class warnings. Differences in tolerability across agents exist but are typically modest at the patient level. Your prescriber will weigh your comorbidities and contraindications to choose the right starting agent.
Can I switch from one to the other?
Yes. Switching is common. The new agent is typically started at its lowest dose and re-titrated rather than jumping to a presumed equivalent.
Is compounded tirzepatide FDA-approved?
No. Compounded tirzepatide is not an FDA-approved drug. The FDA does not review compounded medications for safety, effectiveness, or quality prior to dispensing. Compounded medications are dispensed under personalized prescriptions through state-licensed pharmacies when a prescriber determines a personalized formulation is clinically appropriate.
How long does it take to see results?
Most patients notice appetite suppression within the first few weeks. Measurable weight loss typically becomes apparent by weeks four through eight, depending on dose and individual response. The full effect of the drug becomes clear only at or near the maintenance dose, which for most patients means several months into treatment.
Do results last after stopping the medication?
Weight regain after discontinuation is well-documented across the GLP-1 class. The SURMOUNT and STEP trials both showed significant weight regain in the period after treatment stopped. This is not a failure of willpower. It is the expected biological response. Long-term treatment planning should account for this.
Continue the series
Important Safety Information
This article is for educational purposes only and is not medical advice. Compounded tirzepatide and compounded semaglutide are not FDA-approved drugs. The FDA does not review compounded medications for safety, effectiveness, or quality before they are sold. Compounded medications should only be used when a licensed prescriber determines a personalized formulation is clinically appropriate. Do not start, stop, or modify any prescription medication without speaking with a licensed healthcare provider. If you experience symptoms of a serious reaction, including severe abdominal pain, signs of pancreatitis, vision changes, persistent vomiting, signs of an allergic reaction, or thoughts of self-harm, seek emergency care immediately.
FormBlends sells only compounded semaglutide and compounded tirzepatide through licensed U.S. pharmacies after a telehealth evaluation by an independent prescriber. Eligibility, pricing, and formulation are determined on a case-by-case basis.
About this article
Written by Samuel Okafor, BSN, RN (Registered Nurse, Endocrinology). Medically reviewed by Dr. Anika Rao, MD (Board-Certified Internal Medicine). FormBlends content is reviewed by licensed U.S. clinicians prior to publication. The clinical decisions described above are general education only and should not replace individualized advice from your own healthcare provider.